RAPT Therapeutics Unveils Groundbreaking Atopic Dermatitis Treatment Study
In a significant stride for the field of immunology-based therapeutics, RAPT Therapeutics, Inc., a clinical-stage enterprise, has announced promising results from its Phase 1a/1b clinical trial of zelnecirnon, aimed at treating atopic dermatitis (AD). The corporation’s dedication to crafting oral small molecule therapies for inflammatory diseases and oncology is reflected in the trial outcomes, which have been published in the peer-reviewed journal Allergy.
The trial encompassed a standard single and multiple dose-escalation study involving 72 healthy volunteers, alongside a randomized, double-blind, placebo-controlled study with 31 patients battling moderate-to-severe AD. The data revealed that zelnecirnon was generally well tolerated, with no serious adverse events reported and treatment-emergent adverse events were mild-to-moderate for both the patient and healthy volunteer groups.
Patients with moderate-to-severe AD who were administered zelnecirnon exhibited a 36.3% enhancement from baseline in the Eczema Area and Severity Index (EASI) score after a four-week treatment period. This marked a substantial improvement over the 17.0% enhancement observed in the placebo group. Furthermore, the enterprise noted an additional deepening of response in the two weeks following the conclusion of treatment, with a 53.2% enhancement from baseline in EASI scores at six weeks, in stark contrast to a 9.6% enhancement in the placebo group.
Significant changes were also observed in the transcriptional profile of skin biopsies from zelnecirnon-treated patients that correlated with clinical efficacy measures. Brian Wong, M.D., Ph.D., the Company’s President and CEO, expressed satisfaction with the publication of these results in Allergy and highlighted the implications for the future of Alzheimer’s disease treatment. The institution has also disclosed that its President and CEO will deliver an overview of the firm at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. This presentation is anticipated to shed light on the strategic direction and ongoing projects of the enterprise.
RAPT Therapeutics’ proprietary discovery and development engine has been instrumental in the creation of two novel drug candidates, zelnecirnon and tivumecirnon, which target the C-C motif chemokine receptor 4 (CCR4) for the treatment of inflammation and cancer, respectively. The business is also actively engaged in pursuing a range of targets that are currently in the discovery stage of development.
Recent clinical trial results for zelnecirnon presented by RAPT Therapeutics signal a beacon of hope for patients with moderate to severe atopic dermatitis. The firm’s commitment to fulfilling unmet needs in inflammatory diseases and oncology is manifest in its thorough research and development initiatives. With an unwavering focus on safety and efficacy, the company continues its quest to bring breakthrough treatments to those in need. The publication of these findings in a distinguished journal accentuates the importance of the firm’s contributions to the realm of immunology-based therapeutics.
Source link
